The latest health and social care news and a look at research and development into the treatment of common and rare diseases alike. We also look at the vital changes being made to help deliver effective healthcare through the digital transformation within the NHS.
Today (20 November) Pfizer and BioNTech are sending their drug for approval to the FDA, meaning that the most vulnerable Americans could get the vaccine in December.
Asymptomatic older patients of COVID-19 are one of the most difficult to identify - now, researchers find that delirium could be an indicator of the virus
New research explores the link between ethnicity and ESKD, which finds that Afro-Caribbean patients are four times more likely to undergo COVID hospitalisation.
New data from the Oxford COVID vaccine trial shows that the UK antidote is working well at Phase two, with defining percentages expected after Phase Three is complete.
A significant increase in online searches for "insomnia" signalled to researchers that the first COVID lockdown was hard-hitting on mental health in the US.
Fintan Grant, NHS Digital’s Programme Head for Medicines and Pharmacy charts the recent change in the speed of healthcare delivery in light of COVID-19 including the importance of digital solutions.
Dr Deborah Lee from Dr Fox Online Pharmacy discusses why we need to wear a face covering during the current COVID-19 pandemic, stating the evidence in this illuminating analysis.
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision Group charts the influence of synthetic pesticides on human health and the global ecosystem.
Mhairi Brown, Policy and Public Affairs Manager for Action on Salt, stresses the need for Public Health England to implement a strict and ambitious salt reduction policy.
Eight days after the Pfizer vaccine results (90% effective) brought collective hope to the world, the Moderna vaccine has proven to be 95% effective at fighting COVID-19.
Loneliness during lockdown is one of the most universal afflictions - when researchers studied young adults in the US, they found "alarming" levels of COVID-19 depression.
Over 350 million people suffer from arthritis pain globally, which means significant levels of opiates are used to manage the condition - but what if there was a less addictive treatment?
Gino Martini, RPS Chief Scientist and the Science and Research Team at the Royal Pharmaceutical Society reflect on the role of pharmacy during COVID-19 in delivering accessible, safe and effective care for all.
